Dipayan Sarkar

About

Dipayan Sarkar passed Master of Science from the University of Calcutta in 2015 and has a specialization in Organic Chemistry. He has two years of proficiency in Medicinal Chemistry working as a Research Chemist at the R & D lab in Curadev Pharma Pvt. Ltd. Noida, Uttar -Pradesh, India. He is pursuing a Ph.D. in CSIR-Indian Institute of Chemical Biology as a DST-INSPIRE senior research fellow under the supervision of Dr. Arindam Talukdar. His research area includes target-based drug design and development. Recently, he has been working on a novel target regarding Non-Alcoholic Fatty Liver Disease (NAFLD) and developing a new class of inhibitors of the Top1 enzyme.

Employment

• Baylor College of Medicine Postdoctoral Associate
  2025 - Present
• CSIR - Indian Institute of Chemical Biology DST-INSPIRE Ph.D. Fellow. My Research Involved the Use of state-of-the-Art Techniques in Organic Synthesis, Medicinal Chemistry, Basic Computational Chemistry, in-Vivo and in-Vitro Assays. My Work has Involved Rational Design and Synthesizing Small Molec…
  2017 - 2024
• Curadev Pharma Ltd RESEARCH CHEMIST in Drug Discovery. Developing Small Molecules Targeting Important Protein Targets in Mitigating Cancers & Autoimmune Disease.
  2015 - 2016

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (12)

• Benzoxaboroles in medicinal chemistry: A structure-guided perspective on next-generation therapeutics
  European Journal of Medicinal Chemistry 2026 DOI: 10.1016/j.ejmech.2025.118224
  +Save
• Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis
  Journal of Medicinal Chemistry 2023 DOI: 10.1021/acs.jmedchem.3c01431
  +Save
• Catalyzing the Future of Medicinal Chemistry Research in India
  Journal of Medicinal Chemistry 2023 DOI: 10.1021/acs.jmedchem.3c01304
  +Save
• Bromhexine: Into the spotlight
  Viral, Parasitic, Bacterial, and Fungal Infections 2023 DOI: 10.1016/b978-0-323-85730-7.00032-1
  +Save
• Topoisomerase I inhibitors: Challenges, progress and the road ahead
  European Journal of Medicinal Chemistry 2022 DOI: 10.1016/j.ejmech.2022.114304
  +Save
• Development of a metabolically stable topoisomerase I poison as anticancer agent
  European Journal of Medicinal Chemistry 2020 DOI: 10.1016/j.ejmech.2020.112551
  +Save
• Protective role of ACE inhibitors and ARBs in hypertensive patients suffering from COVID-19
  2020 DOI: 10.22541/au.158955396.63298622
  +Save
• Understanding the riboflavin biosynthesis pathway for the development of antimicrobial agents
  Medicinal Research Reviews 2019 DOI: 10.1002/med.21576
  +Save
• Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity
  Journal of Medicinal Chemistry 2019 DOI: 10.1021/acs.jmedchem.8b01938
  +Save
• Abstract 3510: Small molecule ACSS2 inhibitors target acetate metabolizing tumor cells in hypoxic conditions
  Cancer Research 2018 DOI: 10.1158/1538-7445.am2018-3510
  +Save